The Controversies Surrounding Tocilizumab Administration Following Pathogen-Associated Molecular Pattern (PAMP) Induced by COVID-19
A new corona virus disease (COVID-19) is affected more than 5 million people worldwide to date and has become a global pandemic. Since there is no definitive cure for this life threatening disease, many clinical studies are underway in this regard. Pathogen-associated molecular patterns (PAMP) prompting by coronavirus seems to generate cellular, structural, and functional derangement induced by immune dysregulation and many biological abnormalities including cytokine storm. The role of IL-6 in viral pneumonia and also the impact of its inhibition on the prevention of organ damage are not known yet.IL-6 seems to behave as a double blade evil cytokine, with a valuable role in cell to cell natural physiological communication. Tocilizumab as an inhibitor of interleukin (IL)-6, may interrupt the paracrine system while causing dissemination of bacterial, fungal, and other viral infections, especially COVID-19, who are at high-risk development of sepsis and life-threatening superinfection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of Pharmaceutical Care - 8(2020), 3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shayesteh Gheibi [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Betacoronavirus |
|---|
| doi: |
10.18502/jpc.v8i3.4549 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ063933284 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ063933284 | ||
| 003 | DE-627 | ||
| 005 | 20230309033549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18502/jpc.v8i3.4549 |2 doi | |
| 035 | |a (DE-627)DOAJ063933284 | ||
| 035 | |a (DE-599)DOAJad805e4bb0e34e2d90fe6d908d2c11d1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Shayesteh Gheibi |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Controversies Surrounding Tocilizumab Administration Following Pathogen-Associated Molecular Pattern (PAMP) Induced by COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a A new corona virus disease (COVID-19) is affected more than 5 million people worldwide to date and has become a global pandemic. Since there is no definitive cure for this life threatening disease, many clinical studies are underway in this regard. Pathogen-associated molecular patterns (PAMP) prompting by coronavirus seems to generate cellular, structural, and functional derangement induced by immune dysregulation and many biological abnormalities including cytokine storm. The role of IL-6 in viral pneumonia and also the impact of its inhibition on the prevention of organ damage are not known yet.IL-6 seems to behave as a double blade evil cytokine, with a valuable role in cell to cell natural physiological communication. Tocilizumab as an inhibitor of interleukin (IL)-6, may interrupt the paracrine system while causing dissemination of bacterial, fungal, and other viral infections, especially COVID-19, who are at high-risk development of sepsis and life-threatening superinfection. | ||
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a Betacoronavirus | |
| 650 | 4 | |a Coronavirus Infections | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Pathogen-Associated Molecular Pattern | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Farhad Najmeddin |e verfasserin |4 aut | |
| 700 | 0 | |a Bita Shahrami |e verfasserin |4 aut | |
| 700 | 0 | |a Kourosh Sadeghi |e verfasserin |4 aut | |
| 700 | 0 | |a Mojtaba Mojtahedzadeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Pharmaceutical Care |d Research Center for Rational Use of Drugs (RCRUD), 2013 |g 8(2020), 3 |w (DE-627)DOAJ000129445 |x 23224509 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:3 |
| 856 | 4 | 0 | |u https://doi.org/10.18502/jpc.v8i3.4549 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ad805e4bb0e34e2d90fe6d908d2c11d1 |z kostenfrei |
| 856 | 4 | 0 | |u https://jpc.tums.ac.ir/index.php/jpc/article/view/356 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2322-4630 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2322-4509 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 3 | ||